Join our daily newsletter At The Bell to receive exclusive market insights
- Bio-pharma company MGC Pharmaceuticals (MXC) has progressed its research program using cannabis to develop a treatment for glioblastoma, an aggressive type of brain tumour
- The company tested 18 patient tumour samples using a cannabidiol (CBD) and cannabigerol (CBG) formula
- It found that CBD slowed the viability of the cancer, while CBG increased the death rate of cancerous cells
- Following the successful program, MGC will continue the research, aiming for a human clinical trial next year
- On the market this morning, MGC is in the grey and trading for 2.2 cents per share
MGC Pharmaceuticals (MXC) has further progressed its ongoing research program to develop a treatment for an aggressive brain tumour known as glioblastoma.
The company is currently testing cannabinoid formations on the therapeutically resistant tumour. The research is focused on the use of cannabidiol (CBD) and cannabigerol (CBG) after successful program results in April.
The results
MGC has now successfully completed the in-vitro program, where it tested 18 patient tumour samples using the CBD and CBG formula in different ratios.
The research showed that CBD slowed the tumours’ viability, while CBG increased the cancer cell’s death. Importantly, CBG can destroy glioblastoma stem cells, which is the root of this cancer’s development.
These results are set to significantly progress the company’s research, and it will now turn its attention to researching stem cell lines.
Sadly, Glioblastoma is the most common type of brain cancer and is one of the deadliest types in adults, with only a 6 per cent survival rate four years on from a patient’s diagnosis.
What’s next?
The program is being conducted with National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia.
Following the successful program, NIB and MGC will continue the research, aiming for a human clinical trial next year.
MGC’s Co-Founder and Managing Director, Roby Zomer, is very pleased with the latest results.
“The results we have seen in our preclinical work on glioblastoma have continued to be very encouraging,” he said.
“We are constantly learning more about the therapeutic benefits of medicinal cannabinoids in the treatment of a number of medical conditions and are pleased
to report that the Company will now begin preparations for the next stage of clinical trial work on glioblastoma,” he added.
On the market this morning, MGC is in the grey and trading for 2.2 cents per share at 11:27 am AEDT.
